Abrisqueta, P., González-Barca, E., Ferrà, C., Ríos-Herranz, E., Fernández de la Mata, M., Delgado, J., . . . Yáñez San Segundo, L. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Chicago Style CitationAbrisqueta, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.
MLA CitationAbrisqueta, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.